BTK Inhibitor Dosing for Sustained Occupancy in B-Cell Malignancies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for malignancies such as diffuse large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, Waldenstrom macroglobulinemia, and chronic graft versus host disease are inadequate, necessitating the development of effective therapeutic options.
Innovation Solution
The use of small molecule tyrosine kinase inhibitors, specifically compounds of Formula (III), to target Bruton's tyrosine kinase (BTK) for the treatment of these malignancies, administered in various dosages and combinations with other drugs, achieving significant BTK occupancy and inhibition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for malignancies are used, then existing therapy options are available, but treatment effectiveness is inadequate
Solution Approach 1:
The patent employs parameter changes by developing novel BTK inhibitor compounds with optimized molecular structures (Formula I, II, and III) that achieve superior pharmacokinetic properties and target occupancy compared to existing treatments. The compound design modifies key parameters including molecular weight, lipophilicity, and metabolic stability to enhance treatment effectiveness while maintaining safety
Solution Approach 2:
The patent utilizes composite materials by creating complex multi-component molecular structures that combine various functional groups and moieties. The BTK inhibitor compounds incorporate heterocyclic rings, amide bonds, and aromatic systems that work synergistically to achieve high target affinity and selectivity, representing a composite approach to drug design
2Reliability
If BTK inhibition is achieved through compound administration, then B-cell activation is inhibited, but achieving sufficient BTK occupancy requires optimized dosing
Solution Approach 1:
The patent applies periodic action through structured dosing regimens administered at specific intervals (e.g., once daily, twice daily) to maintain therapeutic BTK occupancy levels. The dosing schedule is optimized to coincide with the pharmacokinetic profile of the compound, ensuring sustained inhibition of B-cell activation while allowing for metabolic clearance between doses
Solution Approach 2:
The patent implements dynamics by adjusting dosing parameters (frequency, duration, and amount) based on observed pharmacokinetic and pharmacodynamic responses. The treatment regimen is tailored to individual patient needs and disease severity, allowing flexible modification of the dosing schedule to optimize BTK occupancy while minimizing side effects
Data Source
AI summary
The present disclosure is directed to the use of a compound of Formula (III) in the treatment of malignancies.